Navigation Links
Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Date:8/19/2007

ong clinical rationale to pursue development of PDX in this setting," said Dr. Horwitz.

Information regarding this study is available at http://www.allos.com or the U.S. government's clinical trials database at http://www.clinicaltrials.gov.

About Cutaneous T-cell Lymphoma

The cutaneous T-cells lymphomas are comprised of a number of non-Hodgkins T-cell lymphomas, including mycosis fungoides and Sezary syndrome, which have their primary manifestations in the skin. According to the Lymphoma Research Foundation, CTCL comprises about 2% to 3% of the estimated 63,000 new cases of non-Hodgkin's lymphoma diagnosed annually.

About PDX (pralatrexate)

PDX is a novel, small molecule chemotherapeutic agent that inhibits dihydrofolate reductase, or DHFR, a folic acid (folate)-dependent enzyme involved in the building of nucleic acid, or DNA, and other processes. PDX was rationally designed for efficient transport into tumor cells via the reduced folate carrier, or RFC-1, and effective intracellular drug retention. We believe these biochemical features, together with preclinical and clinical data in a variety of tumors, suggest that PDX may have a favorable safety and efficacy profile relative to methotrexate and certain other DHFR inhibitors.

About Allos Therapeutics, Inc.

Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent, for w
'/>"/>

SOURCE Allos Therapeutics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
2. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... -- CVS Caremark Corporation (NYSE: CVS ) will ... 2014, at 8:30 a.m. (EDT) with analysts and investors ... An audio webcast of the conference call will ... the CVS Caremark website for all interested parties.  To ... will be archived and available on the web site ...
(Date:7/25/2014)... July 25, 2014  Acsis Inc., the market ... serialization solutions, has recently posted an article, ... current and future needs for companies, extended supply ... supply chain model no longer work today.  The ... the growth of mobile technology, machine to machine ...
(Date:7/25/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... Diagnostic Device An ophthalmic diagnostic device ... or deficiency in the human visual pathway. Ophthalmic devices ... presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, and dry eyes. ...
Breaking Medicine Technology:Acsis Addresses Questions on the Modern Supply Chain 2Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... 2011 Thoratec Corporation (Nasdaq: THOR ), a ... support and restore failing hearts, today announced that it will ... 2011 on Tuesday, November 1. The company will ... operating activities, open to all interested parties, at 1:30 p.m., ...
... 2011 NxStage Medical, Inc. (Nasdaq: ... products, today announced it ranked 141 on Deloitte,s Technology ... media, telecommunications, life sciences and clean technology companies in ... year revenue growth during the period from 2006–2010. NxStage ...
Cached Medicine Technology:Thoratec Schedules Third Quarter Conference Call, Webcast 2NxStage® Ranked Number 141 on the Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™ 2NxStage® Ranked Number 141 on the Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™ 3
(Date:7/25/2014)... Phoenix, AZ (PRWEB) July 25, 2014 ... firm offering discount attorney’s fees with regard to ... Hastings provide a wide range of legal services ... of the negligence of another individual or corporation. Free ... of determining the validity of a potential personal ...
(Date:7/25/2014)... for lymphoma may lower men,s fertility, new research indicates. ... cancers of the body,s white blood cells, often affect ... For men, treatment for these cancers can harm or ... within two years of treatment, the researchers cautioned that ... significant side effect before treatment begins. "While many ...
(Date:7/25/2014)... 2014 Parkulture is proud ... and parkour instructor, Jared “JJ” Woods, will be competing ... American Ninja Warrior. The show will premiere on local ... will rerun on the new Esquire Network on Tuesday, ... resident, has been balancing careers as a professional stuntman ...
(Date:7/25/2014)... The Rottenstein Law Group LLP, ... 25 years of experience advocating for plaintiffs with ... announces the launch of its new website, ... believe they have been harmed by the prescription ... information about the severe adverse side effects allegedly ...
(Date:7/25/2014)... Twins, genes may play a greater role in language ... Researchers found more evidence that language traits, ... largely inherited. The study involving 473 sets of ... of language performance for twins than single-born children) was ... finding disputes hypotheses that attribute delays in early language ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Lymphoma Treatment May Harm, Halt Men's Sperm Production 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 3Health News:Rottenstein Law Group LLP Announces Launch of Xarelto Injury Website 2Health News:Genes May Be Key to Language Delay in Kids 2
... is very rare, affecting approximately one in every 100,000 ... i.e. they are born with empty eye sockets. This ... in the normal way in the first 28 days ... fitted with prosthetic eyes to allow normal facial// development. ...
... which occurs when the heart becomes so enlarged that it ... affects 35 in every 100,000 people. Researchers in the United ... journal Science that a defect in the gene phospholamban may ... the flow of calcium through the heart, enabling it to ...
... using a new imaging technique based on Magnetic Resonance ... now, MRI was used to show how Alzheimer's disease ... for memory and learning. And post-mortem studies revealed how ... the first time a three-dimensional time lapse video of ...
... by scientists at the Johns Hopkins School of Public Health ... have called for urgent research into the impact of soya ... chemical in soya can damage the male reproductive organs. Though ... effect on humans, its effects on rats were so severe ...
... published in the February issue of the British Medical Journal ... more at risk of heart disease later in life than ... live infant in Scotland during the years 1981-85, were identified ... miscarriage or repeated miscarriages. Then, during 1981 to 1999, the ...
... blood has been believed to be the most ... heart disease is associated with increased levels of ... LDL(Low-Density Lipoprotein)or 'bad' cholesterol and HDL(High-Density Lipoprotein) or ... researchers in Canada and Sweden are now putting ...
Cached Medicine News:Health News:Miscarriage during pregnancy and heart disease linked 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: